MEI Pharma (NASDAQ:MEIP) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of MEI Pharma (NASDAQ:MEIP) in a research report issued to clients and investors on Saturday. The firm set a “buy” rating on the stock.

A number of other research analysts have also recently issued reports on MEIP. Stifel Nicolaus reissued a “hold” rating and issued a $7.00 price objective on shares of MEI Pharma in a research note on Friday. TheStreet lowered MEI Pharma from a “c-” rating to a “d+” rating in a research note on Thursday, February 1st.

MEI Pharma Stock Performance

Shares of NASDAQ MEIP opened at $3.33 on Friday. The stock has a market capitalization of $22.18 million, a P/E ratio of 1.12 and a beta of 0.77. The stock’s fifty day moving average is $4.09 and its 200 day moving average is $5.51. MEI Pharma has a 52 week low of $3.21 and a 52 week high of $7.97.

MEI Pharma (NASDAQ:MEIP) last announced its quarterly earnings data on Tuesday, February 13th. The company reported ($1.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.46) by ($0.20). MEI Pharma had a return on equity of 39.72% and a net margin of 39.06%. Equities research analysts forecast that MEI Pharma will post 3.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in MEIP. Jane Street Group LLC acquired a new position in MEI Pharma during the 1st quarter worth approximately $31,000. UBS Group AG boosted its position in MEI Pharma by 115.0% in the fourth quarter. UBS Group AG now owns 132,684 shares of the company’s stock valued at $32,000 after buying an additional 70,959 shares in the last quarter. National Bank of Canada FI bought a new stake in shares of MEI Pharma during the fourth quarter worth $36,000. BNP Paribas Arbitrage SA increased its holdings in shares of MEI Pharma by 483.3% during the second quarter. BNP Paribas Arbitrage SA now owns 62,963 shares of the company’s stock worth $38,000 after buying an additional 52,169 shares in the last quarter. Finally, Morgan Stanley lifted its stake in shares of MEI Pharma by 61.0% in the 4th quarter. Morgan Stanley now owns 184,933 shares of the company’s stock valued at $45,000 after acquiring an additional 70,083 shares during the last quarter. Institutional investors own 52.38% of the company’s stock.

MEI Pharma Company Profile

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.